AxoGen, Inc. to Report Third Quarter Financial Results and Host Conference Call on Wednesday, November 2, 2016
October 19 2016 - 7:00AM
AxoGen, Inc. (NASDAQ:AXGN), a leader in developing and marketing
innovative surgical solutions for peripheral nerve injuries, today
announced that it will report third quarter financial results on
Wednesday, November 2, 2016 after the market closes. AxoGen
management will host an investment-community conference call and
web cast following the release at 4:30PM ET to discuss the
financial results and provide a corporate update.
Investors interested in participating in the
conference call by phone may do so by dialing toll free at (877)
407-0993, or use the direct dial-in number at (201) 689-8795.
Those interested in listening to the conference call live via
the Internet may do so by visiting
http://axogeninc.equisolvewebcast.com/q3-2016.
Following the conference call, a replay will be
available on the company's website at www.axogeninc.com, under
‘investors.’
About AxoGen AxoGen (AXGN) is a
global leader in innovative surgical solutions for peripheral nerve
injuries. AxoGen’s portfolio of products includes Avance® Nerve
Graft, an off-the-shelf processed human nerve allograft for
bridging severed nerves without the comorbidities associated with a
second surgical site, AxoGuard® Nerve Connector, a porcine
submucosa extracellular matrix ("ECM") coaptation aid for
tensionless repair of severed nerves, and AxoGuard® Nerve
Protector, a porcine submucosa ECM product used to wrap and protect
injured peripheral nerves and reinforce the nerve reconstruction
while preventing soft tissue attachments. Along with these core
surgical products, AxoGen also offers AxoTouch™ Two-Point
Discriminator and AcroVal™ Neurosensory & Motor Testing System.
These evaluation and measurement tools assist healthcare
professionals in detecting changes in sensation, assessing return
of sensory, grip and pinch function, evaluating effective treatment
interventions, and providing feedback to patients on nerve
function. The AxoGen portfolio of products is available in the
United States, Canada, the United Kingdom and several European and
international countries.
Cautionary Statements Concerning Forward-Looking
StatementsThis Press Release contains "forward-looking" statements
as defined in the Private Securities Litigation Reform Act of 1995.
These statements are based on management's current expectations or
predictions of future conditions, events or results based on
various assumptions and management's estimates of trends and
economic factors in the markets in which we are active, as well as
our business plans. Words such as "expects", "anticipates",
"intends", "plans", "believes", "seeks", "estimates", "projects",
"forecasts", "continue", "may", "should", "will" variations of such
words and similar expressions are intended to identify such
forward-looking statements. The forward-looking statements may
include, without limitation, statements regarding our growth, our
2016 guidance, product development, product potential, financial
performance, sales growth, product adoption, market awareness of
our products, data validation, our visibility at and sponsorship of
conferences and educational events. The forward-looking statements
are subject to risks and uncertainties, which may cause results to
differ materially from those set forth in the statements.
Forward-looking statements in this release should be evaluated
together with the many uncertainties that affect AxoGen's business
and its market, particularly those discussed in the risk factors
and cautionary statements in AxoGen's filings with the Securities
and Exchange Commission. Forward-looking statements are not
guarantees of future performance, and actual results may differ
materially from those projected. The forward-looking statements are
representative only as of the date they are made, and, except as
required by law, AxoGen assumes no responsibility to update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contacts:
AxoGen, Inc.
Peter J. Mariani, Chief Financial Officer
InvestorRelations@AxoGenInc.com
The Trout Group – Investor Relations
Brian Korb
646.378.2923
bkorb@troutgroup.com
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Sep 2023 to Sep 2024